The APCB is a named author on a number of manuscripts as listed below. It is worthwhile to note that these do not include outcome data as the bank is in its infancy and outcomes won’t be realised for 10-15 years.
Publications in 2018
ETS1 induces transforming growth factor b signalling and promotes epithelial-to-mesenchymal transition in prostate cancer cells.
Rodgers et al., J Cell Biochem 2018; [Impact factor 3.446]
Patient-derived models of abiraterone-and Enzalutamide-resistant prostate cancer reveal sensitivity to ribosome-directed therapy.
Lawrence et al., Eur Urol 2018; [Impact factor 17.581]
Schumacher et al., Nat Genet 2018; [Impact factor 27.125]
Martin et al., Sci Rep 2018; [Impact factor 4.122]
Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts.
Seibert et al., BMJ 2018; [Impact factor 23.295]
Intraductal carcinoma of the prostate can evade androgen deprivation, with emergence of castrate-tolerant cells.
Porter et al., BJU 2018; [Impact factor 4.387]
Publications in 2017
A micro satellite repeat in PCA3 long non-coding RNA is associated with prostate cancer risk and aggressiveness.
Lai et al., Sci Rep 2017; [Impact factor 4.122]
Extracellular vesicles for personalised therapy decision support in advanced metastatic cancers and its potential impact for prostate cancer.
Soekmadji et al., Prostate 2017; [Impact factor 3.565]
Lophatananon et al., Br J Cancer 2017; [Impact factor 5.569]
Kallikrein-related peptidase 4 induces cancer-associated fibroblast features in prostate-derived stromal cells.
Kryza et al., Mol Oncol 2017; [Impact factor 5.314]
Yow et al., Infect Agent Cancer 2017; [Impact factor 1.718]
Publications in 2016
Commentary on “A large0scale analysis of genetic variants within putative miRNA binding sites in prostate cancer.”
Lin D., Urol Oncol 2016; [Impact factor 3.767]
A novel class of Hsp90 C-terminal modulators have pre-clinical efficacy in prostate tumour cells without induction of a heat shock response.
Armstrong et al., Prostate 2016; [Impact factor 3.565]
Assays for qualification and quality stratification of clinical biospecimens used in research: A technical report from the ISBER biospecimen science working group.
Betsou et al., Biopreserv Biobank 2016; [Impact factor 1.698]
Genome-wide meta-analyses of breast, ovarian and prostate cancer association studies identify multiple new susceptibility loci shared by at least two cancer types.
Kar et al., Cancer Discov 2016; [Impact factor 19.453]
High expression of TRO2P2 characterizes different cell subpopulations in androgen-sensitive and androgen-independent prostate cancer cells.
Xie et al., Oncotarget 2016; [Impact factor 5.008]
Publications in 2015
Lai et al., BMC Genomics 2015; [Impact factor 3.729]
Szulkin et al., Cancer Epidemiol Biomarkers 2015; [Impact factor 4.125]
Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans.
Amin Al Olama et al., Hum Mol Genet 2015; [Impact factor 5.985]
Szulkin et al., Prostate 2015; [Impact factor 3.565]
Stegeman et al., Cancer Discov 2015; [Impact factor 19.453]
Publications in 2014
Commentary on “Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array”.
Olumi., Urol Oncol 2014; [Impact factor 3.767]
Moon et al., Oncogene 2014; [Impact factor 8.459]
Publications in 2013
A preclinical xenograft model identifies castration-tolerant cancer-repopulating cells in localized prostate tumors.
Toivanen et al., Sci Trans Med 2013; [Impact factor 16.796]
Selth et al., British Journal of Cancer 2013; [Impact factor 5.082]
A bioengineered microenvironment to quantitatively measure the tumorigenic properties of cancer-associated fibroblasts in human prostate cancer.
Clark et al., Biomaterials 2013; [Impact factor 7.404]
Lawrence et al.,Nat Protoc 2013; [Impact factor 9.924]
A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease.
Amin Al Olama et al., Hum Mol Genet 2013; [Impact factor 7.636]
Eeles et al., Nat Genet 2013; [Impact factor 32.209]
Characterization of the prostate cancer susceptibility gene KLF6 in human and mouse prostate cancers.
Chiam et al., The Prostate 2013; [Impact factor 3.565]
Common variation in kallikrein genes KLK5, KLK6, KLK12, and KLK13 and risk of prostate cancer and tumor aggressiveness.
Lose et al., Urol Oncol 2013; [Impact factor 3.216]
Publications in 2012
Lose et al.,PLOS one 2012; [Impact factor 4.092]
Centenera et al.,Clin Cancer Res 2012; [Impact factor 7.742]
Toivanen et al., J Steroid Biochem Mol Biol 2012; [Impact factor 3.053]
A gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease.
Thompson et al., Int J Cancer 2012; [Impact factor 5.444]
Taylor et al., Stem Cells 2012; [Impact factor 7.781]
The kallikrein 14 gene is down-regulated by androgen receptor signalling and harbours genetic variation that is associated with prostate tumour aggressiveness.
Lose et al., Biol Chem 2012; [Impact factor 2.965]
Tindall et al., The Prostate 2012; [Impact factor 3.565]
Publications in 2011
Seven novel prostate cancer susceptibility loci identified by a multi-stage genome-wide association study.
Kote-Jarai et al., Nature Genetics 2011; [Impact factor 35.532]
Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study.
Eeles et al., Nat Genet Letters 2011; [Impact factor 32.209]
A Replication Study Examining Novel Common Single Nucleotide Polymorphisms Identified Through a Prostate Cancer Genome-wide Association Study in a Japanese Population.
Batra et al., Am J Epidemiol 2011; [Impact factor 5.216]
Reactivation of Embryonic Nodal Signaling Is Associated With Tumor Progression and Promotes the Growth of Prostate Cancer Cells.
Lawrence et al., Prostate 2011; [Impact factor 3.485]
Publications in 2010
Kallikreins on Steroids: Structure, Function, and Hormonal Regulation of Prostate-Specific Antigen and the Extended Kallikrein Locus.
Lawrence et al., Endo Reviews 2010; [Impact factor 19.929]
Global Levels of Specific Histone Modifications and an Epigenetic Gene Signature Predict Prostate Cancer Progression and Development.
Bianco-Miotto et al., CEBP 2010; [Impact factor 4.123]
Comparative Biomarker Expression and RNA Integrity in Biospecimens Derived from Radical Retropubic and Robot-Assisted Laparoscopic Prostatectomies.
Ricciardelli et al., CEBP 2010; [Impact factor 4.123]
Comprehensive analysis of the cytokine-rich chromosome 5q31.1 region suggests a role for IL-4 gene variants in prostate cancer risk.
Tindall et al., Carcinogenesis 2010; [Impact factor 5.702]
Betsou et al., CEBP 2010; [Impact factor 4.123]
Publications in 2009
Betsou et al., CEBP 2009;[Impact factor 4.123]